Company / Interest Expense
Vistagen Therapeutics, Inc. Interest Expense History
FY2011-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$19.9K
FY2023
5-year range
$1.6K / $770.8K
FY2019-FY2023
Trend
+1143.8%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense changed +1144% YoY in FY2023, a notable deviation from the 7-year average annual change of +225%.
Based on SEC 10-K filings.
$19,900 in FY2023 with a 5-year CAGR of +34.0%.
Improved from $30,100 to $19,900 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +34.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +34.0%, indicating consistent growth.
- In FY2023, interest expense increased 1143.8% year-over-year.
- Peak interest expense was recorded in FY2011.
- Lowest interest expense in the period was in FY2012.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $19.9K | +1143.8% |
| FY2022 | $1.6K | -94.7% |
| FY2021 | $30.1K | +554.3% |
| FY2018 | $4.6K | -99.4% |
| FY2017 | $770.8K | +183.7% |
| FY2014 | -$920.7K | +51.4% |
| FY2012 | -$1.9M | -160.7% |
| FY2011 | $3.1M | - |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026